Therefore, BLACAT1 can differentiate between metastatic and non-metastatic stages of BCs. This elevation was positively correlated with disease progression. 2), and higher levels were detected in the T3 stage with a mean value of (5.2 ± 0.6). Furthermore, in the invasive stages, its levels started to elevate in the T2 stage (1.2 ± 0. BLACAT1 was downregulated in superficial stages (T0 = 0.09 ± 0.02 and T1 = 0.5 ± 0.1) compared to healthy control.

The expression levels of urinary BLACAT1 were detected by qRT-PCR assay in seventy (70) BC patients with different TNM grades (T0-T3) and twelve (12) healthy subjects as control. Therefore, this study aimed to determine the expression and clinical significance of urinary lncRNA BLACAT1 as a non-invasively diagnostic and prognostic biomarker to detect and differentiate BCs stages. Hence, finding sensitive and specific biomarkers for predicting the diagnosis and prognosis of patients with BC is critically needed. In addition, only a limited number of biomarkers are available for diagnosing BC compared to other cancers. The most urgent problem in BCs is the high recurrence rate as two-thirds of non-muscle-invasive bladder cancer (NMIBC) will develop into muscle-invasive bladder cancer (MIBC), which retains a feature of rapid progress and metastasis. Bladder cancer (BC) is recorded as the fifth most common cancer worldwide with high morbidity and mortality.

Graphpad prism licence